Collaborations | Business Development


Heptares is leveraging its transformational platform to generate a broad and deep pipeline of first-in-class and best-in-class GPCR-targeted medicines. We are focused today on advancing novel drug candidates, both NCEs and antibodies, in the areas of CNS and metabolic disease.

The scope of the opportunity using the Heptares approach extends well beyond our growing pipeline. Large and untapped regions of the GPCR target universe, previously regarded as undruggable, are now tractable for rational drug discovery using the Heptares approach.

We welcome the interest from pharmaceutical and biotechnology companies seeking access to this broader GPCR target landscape through collaboration with Heptares.

For more information on outlicensing or partnering opportunities, please contact:

Barry Kenny,

Chief Business Officer

Click on diagram to enlarge

© 2012-2017 Heptares Therapeutics